Characterization of primary and metastatic pancreatic tumors in pancreatic ductal adenocarcinoma (PDAC)

被引：0
|
作者：
Martinez-Muniz, Andres E. [1 ]
Sivanand, Sharanya [2 ]
Vander Heiden, Matthew [2 ]
机构：
[1] Univ Puerto Rico Mayaguez, Mayaguez, PR USA
[2] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-4358
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4358
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Proteome profiling of pancreatic ductal adenocarcinoma (PDAC) primary tumors in Caucasian, African American and Latinx patients.
    Law, Henry C. H.
    Riner, Andrea N.
    Trevino, Jose G.
    Woods, Nicholas T.
    CANCER RESEARCH, 2021, 81 (22) : 4 - 4
  • [22] Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe
    Javed, Muhammad Ahsan
    Beyer, Georg
    Le, Nha
    Vinci, Alessio
    Wong, Helen
    Palmer, Daniel
    Morgan, Robert D.
    Lamarca, Angela
    Hubner, Richard A.
    Valle, Juan W.
    Alam, Salma
    Chowdhury, Sumsur
    Ma, Yuk Ting
    Archibugi, Livia
    Capurso, Gabriele
    Maisonneuve, Patrick
    Neesse, Albrecht
    Sund, Malin
    Schober, Marvin
    Krug, Sebastian
    PANCREATOLOGY, 2019, 19 (01) : 97 - 104
  • [23] MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
    Prinz, Christian
    Fehring, Leonard
    Frese, Robin
    CELLS, 2022, 11 (15)
  • [24] Pancreatic ductal adenocarcinoma: metastatic disease
    Munoz Martin, A. J.
    Adeva, J.
    Martinez-Galan, J.
    Reina, J. J.
    Hidalgo, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12): : 1423 - 1429
  • [25] Pancreatic ductal adenocarcinoma: metastatic disease
    A. J. Muñoz Martín
    J. Adeva
    J. Martínez-Galán
    J. J. Reina
    M. Hidalgo
    Clinical and Translational Oncology, 2017, 19 : 1423 - 1429
  • [26] Hereditary pancreatitis (HP) and the risk of pancreatic ductal adenocarcinoma (PDAC)
    Howes, N
    Lerch, MM
    Charnley, R
    Mössner, J
    Endres, S
    Deviere, J
    Verreman, V
    Lucidi, V
    Ohla, A
    Ihse, I
    Imrie, C
    Steenbergan, W
    Poll, A
    Greenhalf, W
    Ellis, I
    Mountford, R
    Whitcomb, DC
    Neoptolemos, JP
    GUT, 2002, 50 : A43 - A43
  • [27] Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)
    Marquez, J. P.
    Lucero-Diaz, P. A.
    Matute-Briseno, J. A.
    Rosas-Delgado, M. O.
    Camacho-Hernandez, A.
    Cortez-Vargas, Y.
    Nava-Sanchez, I.
    Montano, G. T.
    Montijo-Fernandez, L. N.
    Perez-Astorga, M. A.
    ANNALS OF ONCOLOGY, 2018, 29 : 44 - 44
  • [28] Efficacy of olaparib therapy in metastatic pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD).
    Tan, Elaine
    Hicks, James Kevin
    Blue, Kirsten
    Kim, Richard D.
    Carballido, Estrella M.
    Kim, Dae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Neuroplastic Changes in a Mouse Model of Pancreatic Ductal Adenocarcinoma (PDAC)
    Stopczynski, Rachelle E.
    DePinho, Ronald A.
    Ying, Haoqiang
    Schwartz, Erica S.
    Albers, Kathryn M.
    Davis, Brian M.
    Bielefeldt, Klaus
    GASTROENTEROLOGY, 2010, 138 (05) : S62 - S62
  • [30] Safety and efficacy of chemotherapy in older adults with locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC)
    Ostios-Garcia, Lorena
    Saade, Patricia
    Grossman, Joseph Elan
    Lanniello, Leanne
    Bullock, Andrea J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345